When Thiamine Mononitrate Is Filled into Low-Moisture HPMC Capsules, What Degradation Mechanisms Govern Stability?

In hard shell capsule filling suites maintained at 35–45% RH and 18–22°C, the primary degradation vector for thiamine mononitrate is not thermal but moisture-mediated hydrolysis of the methylene bridge linking the pyrimidine and thiazole rings; consequently, low-moisture HPMC capsule shells with shell moisture 4–6% are specified instead of gelatin shells whose equilibrium water activity can exceed 0.45 at 25°C. A single-entity B1 capsule commonly contains 10–100 mg thiamine mononitrate in a fill weight of 200–400 mg, yielding an API addition ratio of 5–30% w/w; B-complex capsule formulations may reduce this to 1–3% w/w because the inclusion of riboflavin, niacinamide, and pyridoxine requires larger diluent volumes. Dosator-type capsule machines require granule particle size with a D50 of 100–250 µm and a loss on drying of 2.0–3.5% to prevent caking and fill weight drift; dry granulation by roller compaction is therefore preferred over wet granulation for capsule-grade material, with roll pressure 20–40 kN and screen size 1.0 mm. Finished capsules are tested for dissolution per USP <711> using 0.1 N HCl, content uniformity per USP <905>, and aerobic microbial enumeration per USP <61> and USP <62> because nonsterile oral solid dosage forms must meet acceptance criteria for total aerobic count and absence of Escherichia coli. Terminal product types include HPMC capsules, pullulan capsules, and two-piece hard gelatin capsules when the moisture specification is tightened and desiccant sachets are added; however, gelatin formulations without a desiccant show higher thiamine degradation at 40°C/75% RH after 3 months, and published data for this specific configuration is limited.

Within high-volume direct compression lines producing film-coated B-complex tablets, thiamine mononitrate functions as the non-hygroscopic alternative to thiamine hydrochloride because the mononitrate salt reduces moisture uptake at 40% RH to below that observed for the hydrochloride salt; however, the plate-like crystal habit of the milled API imposes a bulk density range of 0.45 g/mL to 0.65 g/mL and a Carr index frequently above 30, which necessitates roller compaction or wet granulation before compression on rotary presses operating at 60–80 rpm. In this application, the API is blended with microcrystalline cellulose at 20–35% w/w, spray-dried lactose at 15–25% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.5% w/w to produce a 500–600 mg core; label claims typically require 1.5 mg, 5 mg, 10 mg, 50 mg, or 100 mg thiamine mononitrate per tablet, placing the API addition ratio between 0.5% w/w and 16.7% w/w. The downstream process for wet granulation uses an isopropyl alcohol–water mixture at 70:30 v/v with povidone K30 as binder because aqueous granulation at high shear can initiate hydration and browning at dryer inlet temperatures above 60°C; granule moisture is controlled to 2.0–3.0% before lubrication. Compliance for this scenario includes assay and related substances by HPLC per USP <621>, content uniformity per USP <905>, dissolution per USP <711> in 0.1 N HCl at 37°C, and elemental impurities per ICH Q3D(R2). The terminal dosage forms are film-coated tablets, sugar-coated tablets, and bilayer B-complex tablets. A documented operational boundary exists when the formulation contains reducing sugars or sulfite-containing excipients: thiamine undergoes nucleophilic cleavage at the methylene bridge in the presence of bisulfite, producing pyrimidine and thiazole moieties, so such combinations are excluded from direct compression formulations.

Because the low-moisture environment and acidic pH upon reconstitution stabilize the thiazolium ring, effervescent granule lines processing citric acid–sodium bicarbonate dry blends at 20–25% RH use thiamine mononitrate as the API of choice; thiamine hydrochloride would cause visible specks and accelerated hydrolytic cleavage in the presence of sodium bicarbonate. Typical sachet fill weights of 4–8 g deliver 10–50 mg thiamine mononitrate, representing 0.2–1.0% w/w of the dry mix; effervescent tablet weights of 3–5 g use the same API ratio but require compression at 15–25 kN with 0.5% w/w sodium stearyl fumarate as a water-soluble die lubricant because magnesium stearate reduces wettability and causes clouding upon reconstitution. The production process granulates the citric acid and sodium bicarbonate separately with 5% w/v povidone in isopropanol, dries the granules in a fluid-bed dryer at inlet air temperature 45–55°C to final moisture 0.5–1.5%, and then blends the API with 0.1–0.3% sodium benzoate before final compression or sachet filling. Dissolution testing is performed per USP <711> in 0.1 N HCl; content uniformity per USP <905>; residual solvent limits for isopropanol are set according to ICH Q3C class 3. Packaging requires aluminium foil laminate sachets with a water vapour transmission rate below 0.01 g/m²/day at 38°C/90% RH to prevent premature acid-base reaction during storage. Terminal product types are effervescent tablets, granules for oral solution, and instant drink powders. The formulation is incompatible with magnesium stearate and with sodium lauryl sulfate above 0.1% w/w, which can generate foam and reduce dissolution clarity.

If Thiamine Mononitrate Is Selected for a Sterile Dry-Fill Parenteral, Solubility at 25°C Becomes the Binding Constraint

Thiamine mononitrate exhibits aqueous solubility of approximately 27 mg/mL at 25°C, which excludes the preparation of 100 mg/mL parenteral solutions commonly associated with thiamine hydrochloride; a dry powder vial containing 100 mg of micronized sterile thiamine mononitrate can be reconstituted with 10 mL Water for Injection to yield a 10 mg/mL solution, provided the solution pH is adjusted to 3.5–4.5 with dilute hydrochloric acid. The sterile dry-fill process uses aseptic crystallization and micronization of the API to a D90 below 20 µm, followed by aseptic blending with mannitol at 200 mg per vial as a bulking agent; terminal sterilisation by moist heat at 121°C for 15 min is generally incompatible because the thiazolium ring undergoes ring opening and loss of potency exceeds 5% after a single cycle. Sterility acceptance is verified per USP <71>, bacterial endotoxins per USP <85> with a limit of 0.25 EU/mg, particulate matter per USP <788>, and uniformity of dosage units per USP <905>; stability is evaluated under ICH Q1A(R2) long-term conditions of 25°C/60% RH and accelerated 40°C/75% RH. The addition ratio in the dry powder is 33.3% w/w thiamine mononitrate relative to total fill weight of 300 mg, but published data for this specific sterile dry-fill configuration is limited, and formulation development should include forced degradation studies per ICH Q1B. Terminal product types are sterile powder for injection and lyophilized cakes; the reconstituted solution is intended for immediate use and is not stable for extended periods at room temperature due to oxidative degradation catalyzed by trace copper and iron ions, which must be chelated with edetate disodium at 0.01% w/v in the vehicle.

Formulation Constraints in Low-Acid Medical Food Dry Blends

In powdered enteral nutrition and medical food products intended for oral or tube feeding, thiamine mononitrate is incorporated at levels that align with Codex STAN 72-1981 and EU Commission Delegated Regulation (EU) 2016/128; label claims are expressed as mg per 100 kcal or mg per 100 g of reconstituted product. For a standard enteral formula providing 1.5 kcal/mL on reconstitution, thiamine mononitrate is added at 0.12–0.45 mg/100 kcal, equivalent to 0.0003–0.0012% w/w of dry powder; in high-protein medical food powders the level may reach 1.4 mg/100 g. Dry blending in ribbon or paddle mixers requires a premix of the micronized API with maltodextrin at a 1:100 ratio before addition to the main blend; mixing time is 15–25 min at 15–20 rpm, and finished powder moisture is controlled below 3.5% to prevent caking and thiamine degradation. The process includes indirect steam injection during spray drying of the base formula, but the heat-labile thiamine is added in a separate post-drying blending step because exposure to 80–90°C outlet air during spray drying can reduce potency by more than 10% in carbohydrate-rich matrices. Microbial limits follow Codex CAC/RCP 66-2008 and USP <61>/USP <62> where the product is classified as a nonsterile nutritional powder; heavy metals are governed by ICH Q3D for the pharmaceutical-grade API input. Terminal product types are enteral nutrition powder in sachets, medical food modules, and oral rehydration nutrition packets. The main incompatibility in this application is sodium metabisulfite used as a preservative in some liquid ready-to-hang feeds; when thiamine mononitrate is added to such systems, the bisulfite cleaves the methylene bridge and total thiamine content declines to below 90% of label claim within 24 h at room temperature.

Although thiamine mononitrate is often viewed as a material for conventional tablets, its crystalline form with a particle size D90 below 75 µm permits incorporation into taste-masked oral disintegrating granules for pediatric and geriatric populations, provided the API is pre-dispersed in an aqueous suspension of ethylcellulose and subsequently spray-layered onto sugar spheres in a fluid-bed coater. Typical layering formulations deliver 5–25 mg thiamine mononitrate per 1 g of finished granules; the API content is 0.5–2.5% w/w of the total granule mass. Spray layering is conducted in a Wurster column with inlet air temperature 50–60°C, atomization pressure 1.5–2.5 bar, and spray rate 8–15 g/min per kg of substrate; final granules are dried to moisture 1.5–2.5% and sieved through a 1.0 mm screen to remove agglomerates. The taste-masking coating uses amino methacrylate copolymer, which must be cured at 40°C for 2 h; residual ethanol content is controlled to below 0.5% because higher solvent levels plasticize the coating and initiate thiamine degradation at the polymer–API interface. Compliance includes dissolution per USP <711> using water or 0.1 N HCl, content uniformity per USP <905>, and aerobic microbial enumeration per USP <61>/62. Terminal product types are oral disintegrating granules, sprinkle capsules for opening, and stick pack formats; published data for this specific pediatric sprinkle configuration is limited, so pilot-scale forced degradation studies are required before scale-up.